دورية أكاديمية
[Clinical efficacy and safety evaluation of acupuncture combined with moxibustion in treatment of allergic rhinitis].
| العنوان: | [Clinical efficacy and safety evaluation of acupuncture combined with moxibustion in treatment of allergic rhinitis]. |
|---|---|
| المؤلفون: | Ma W; College of Acupuncture-Moxibustion and Tuina, Hunan University of Chinese Medicine, Changsha 410208, China; Preventive Treatment Center, Yulin Hospital of Chinese Medicine, Yulin 719000, Shaanxi Province., Zhai CT; The Third Clinical College, Shanxi University of Chinese Medicine, Taiyuan 030024., Shang HM; Preventive Treatment Center, Yulin Hospital of Chinese Medicine, Yulin 719000, Shaanxi Province., Xu XS; The Third Clinical College, Shanxi University of Chinese Medicine, Taiyuan 030024., Zheng T; Preventive Treatment Center, Yulin Hospital of Chinese Medicine, Yulin 719000, Shaanxi Province., Tian YF; The Third Clinical College, Shanxi University of Chinese Medicine, Taiyuan 030024. |
| المصدر: | Zhen ci yan jiu = Acupuncture research [Zhen Ci Yan Jiu] 2022 Apr 25; Vol. 47 (4), pp. 336-42. |
| نوع المنشور: | Journal Article |
| اللغة: | Chinese |
| بيانات الدورية: | Publisher: Institute Of Acupuncture And Moxibustion Country of Publication: China NLM ID: 8507710 Publication Model: Print Cited Medium: Print ISSN: 1000-0607 (Print) Linking ISSN: 10000607 NLM ISO Abbreviation: Zhen Ci Yan Jiu Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Beijing : Institute Of Acupuncture And Moxibustion Original Publication: Beijing, China : Published and distributed by World Books, [1980- |
| مواضيع طبية MeSH: | Acupuncture Therapy* , Interleukin-27* , Moxibustion* , Rhinitis, Allergic*/therapy, Forkhead Transcription Factors ; Humans ; Immunoglobulin E ; Interleukin-17 ; Interleukin-33 ; Nuclear Receptor Subfamily 1, Group F, Member 3 ; Quality of Life ; Treatment Outcome |
| مستخلص: | Objective: To evaluate the clinical efficacy and safety of acupuncture combined with moxibustion on allergic rhinitis. Methods: Using the random number table, 80 patients with allergic rhinitis were divided into a medication group and an acupuncture combined with moxibustion (acu-mox) group, 40 cases in each one. In the medication group, ioratadine tables were prescribed for oral administration, one tablet daily for 10 days as 1 session , 3 sessions of treatment were required. In the acupuncture combined with moxibustion group, bilateral Yingxiang (LI20), Yintang (EX-HN3), bilateral Hegu (LI4) and bilateral Shenshu (BL23) were selected as the main points and stimulated with acupuncture and moxibustion; and the acupoint prescription was modified according to symptoms. This combined treatment was given once every day, stimulating for 30 min each time, and 10 treatments made 1 course, for 3 courses of treatment totally. Before and after treatment, the scores for symptoms and physical signs, as well as the score of rhino-conjunctivitis related quality of life scale (R-QOL) were evaluated separately. The sample of the inferior turbinate mucosa tissue was collected and the distribution of eosinophil (EOS) was scored using HE staining and Sheldeny evaluation. Using enzyme-linked immunosorbent assay (ELISA), the contents of serum immunoglobulin E (IgE), retinoic-acid-receptor-related orphan nuclear receptor γt (RORγt), forkhead box protein P3 (Foxp3), interleukin-17 (IL-17), IL-27 and IL-33 were determined. The clinical efficacy was evaluated in the patients with allergic rhinitis of two groups and all the adverse reactions were recorded during treatment. Results: The scores of symptoms and physical signs as well as the score of R-QOL, and EOS distribution score and the contents of serum IgE, RORγt, IL-17 and IL-33 were all reduced as compared with those before treatment in each group ( P <0.05), and the contents of serum Foxp3 and IL-27 were increased as compared with those before treatment in each group ( P <0.05). After treatment, the scores of symptoms and physical signs as well as the score of R-QOL, and the contents of serum IgE, RORγt and IL-33 in the acu-mox group were lower than those in the medication group ( P <0.05), and the contents of serum Foxp3 and IL-27 were higher than those of the medication group ( P <0.05). The total effective rate of the acu-mox group was 100.0% (40/40), significantly higher than 82.5% (33/40) in the medication group ( P <0.05). No ob-vious adverse reaction was found in either group during and after treatment. Conclusion: Acupuncture combined with moxibustion is significantly effective and safe in treatment of allergic rhinitis. Its effect mechanism may be related to the balance modulation of Th1/Th2 and Th17/Treg cells mediated by naive CD4 + T cells. |
| فهرسة مساهمة: | Keywords: Acupuncture combined with moxibustion; Allergic rhinitis; Clinical efficacy; Safety evaluation Local Abstract: [Publisher, Chinese] 目的： 评价针刺联合艾灸治疗过敏性鼻炎(AR)的临床疗效及安全性。 方法： 选取AR患者80例，采用随机数字表法分为药物组与针刺联合艾灸组，每组40例。药物组给予氯雷他定片口服，每日1片，10 d为1个疗程，治疗3个疗程；针刺联合艾灸组以迎香(双)、印堂、合谷（双）、肾俞（双）为主穴进行针刺和艾灸，并随证加减穴位，每日治疗1次，每次30 min，10次为1个疗程，治疗3个疗程。治疗前后分别评定临床症状评分、临床体征评分及鼻-结膜相关生活量表评分；刮取部分下鼻甲黏膜组织表面的分泌物，采用HE染色法及Sheldeny评价法进行嗜酸性粒细胞(EOS)分布程度评分；采用酶联免疫吸附法测定血清免疫球蛋白E(IgE)、维甲酸孤儿受体γt(RORγt)、叉头盒蛋白P3(Foxp3)、白细胞介素-17(IL-17)、IL-27、IL-33含量。评价两组AR患者的临床疗效，并记录治疗期间出现的所有不良反应。 结果： 两组患者临床症状评分、临床体征评分及鼻-结膜相关生活量表评分、EOS分布评分及血清IgE、RORγt、IL-17、IL-33含量均较本组治疗前降低( P <0.05)，血清Foxp3、IL-27含量较本组治疗前升高( P <0.05)。治疗后针刺联合艾灸组临床症状评分、临床体征评分及鼻-结膜相关生活量表评分及血清IgE、RORγt、IL-33含量低于药物组( P <0.05)，血清Foxp3、IL-27含量高于药物组( P <0.05)。针刺联合艾灸组总有效率为100.0%(40/40)，显著高于药物组的82.5%(33/40， P <0.05)。治疗期间及治疗后，两组患者均未出现明显不良反应。 结论： 针刺联合艾灸治疗AR疗效显著，安全性好，其治疗机制可能与调控幼稚CD4 + T细胞介导的辅助性T细胞（Th）1/Th2、Th17/调节性T细胞平衡有关。. |
| المشرفين على المادة: | 0 (Forkhead Transcription Factors) 0 (Interleukin-17) 0 (Interleukin-27) 0 (Interleukin-33) 0 (Nuclear Receptor Subfamily 1, Group F, Member 3) 37341-29-0 (Immunoglobulin E) |
| تواريخ الأحداث: | Date Created: 20220429 Date Completed: 20220503 Latest Revision: 20220503 |
| رمز التحديث: | 20221213 |
| DOI: | 10.13702/j.1000-0607.20210315 |
| PMID: | 35486013 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1000-0607 |
|---|---|
| DOI: | 10.13702/j.1000-0607.20210315 |